EUVIMEDEUVIMED entdecken
Crossref

Cardioprotective Effect of Empagliflozin and Circulating Ketone Bodies During Acute Myocardial Infarction

Carlos G Santos-Gallego iD, Juan Antonio Requena-Ibáñez, Belen Picatoste, Brian Fardman, Kiyotake Ishikawa iD, Renata Mazurek iD, Michael Pieper, Samantha Sartori, Jorge Rodriguez-Capitán iD, Valentin Fuster, Juan J Badimon iD

Circulation: Cardiovascular Imaging · 2023-04 · 16 (4)

DOI: 10.1161/circimaging.123.015298 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Circulation: Cardiovascular Imaging, 2023-04. Verfasst von Carlos G Santos-Gallego und 10 weiteren Autor:innen. Beteiligte Einrichtung: Atherothrombosis Research Unit (C.G.S.-G., J.A.R.-I., B.F., J.J.B.), Icahn School of Medicine at Mount Sinai, New York. Hauptthemen laut MEDLINE: Myocardial Infarction, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 76-mal zitiert (Crossref) und nennt 41 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

SGLT2i (sodium-glucose cotransporter-2 inhibitors) improve clinical outcomes in patients with heart failure, but the mechanisms of action are not completely understood. SGLT2i increases circulating levels of ketone bodies, which has been demonstrated to enhance myocardial energetics and induce reverse ventricular remodeling. However, the role of SGLT2i or ketone bodies on myocardial ischemia reperfusion injury remains in the dark. The objective of this study is to investigate the cardioprotective potential of empagliflozin and ketone bodies during acute myocardial infarction (MI).

Methods

We used a nondiabetic porcine model of ischemia reperfusion using a percutaneous occlusion of proximal left anterior descending artery for 45 minutes. Animals received 1-week pretreatment with either empagliflozin or placebo prior to MI induction. Additionally, a third group received intravenous infusion of the ketone body BOHB (beta-hydroxybutyrate) during the MI induction. Acute effects of the treatments were assessed 4-hour post-MI by cardiac magnetic resonance and histology (thioflavin for area at risk, triphenyltetrazolium chloride staining for MI size). All animals were euthanized immediately postcardiac magnetic resonance, and heart samples were collected.

Results

The area at risk was similar in all groups. Empagliflozin treatment increased BOHB levels. Empagliflozin-treated animals showed significantly higher myocardial salvage, smaller MI size (both by cardiac magnetic resonance and histology), less microvascular obstruction, and improved cardiac function (left ventricle ejection fraction and strain). Furthermore, empagliflozin-treated animals demonstrated reduced biomarkers of cardiomyocyte apoptosis and oxidative stress compared with placebo. The BOHB group showed similar results to the empagliflozin group.

Conclusions

One-week pretreatment with empagliflozin ameliorates ischemia reperfusion injury, reduces MI size and microvascular obstruction, increases myocardial salvage, preserves left ventricle systolic function, and lowers apoptosis and oxidative stress. Periprocedural intravenous infusion of BOHB during myocardial ischemia also induces cardioprotection, suggesting a role for BOHB availability as an additional mechanism within the wide spectrum of actions of SGLT2i.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myocardial InfarctionSodium-Glucose Transporter 2 InhibitorsAnimalsKetone BodiesSwineBenzhydryl CompoundsGlucosides

Stichwörter der Autor:innen

empagliflozinglucoseketone bodiesmyocardial infarctionreperfusion

Substanzen

Ketone BodiesSodium-Glucose Transporter 2 InhibitorsempagliflozinBenzhydryl CompoundsGlucosides

Autor:innen und Institutionen

  • Atherothrombosis Research Unit (C.G.S.-G., J.A.R.-I., B.F., J.J.B.), Icahn School of Medicine at Mount Sinai, New York.
  • Mount Sinai Heart (C.G.S.-G., J.A.R.-I., B.F., K.I., R.M., S.S., V.F., J.J.B.), Icahn School of Medicine at Mount Sinai, New York.
  • Biochemistry Department, Weill Cornell Medical College, New York (B.P.).
  • Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany (M.P.).
  • Centro de Investigación en Red de Enfermedades Cardiovasculares (CIBERCV), Cardiology Department, Hospital Universitario Virgen de la Victoria, Spain (J.R.-C.).
  • IBIMA-Plataforma BIONAND, Universidad de Málaga, Spain (J.R.-C.).

ORCID-Profile: Carlos G Santos-Gallego, Kiyotake Ishikawa, Renata Mazurek, Jorge Rodriguez-Capitán, Juan J Badimon

Zitieren

APA

Santos-Gallego, C. G., Requena-Ibáñez, J. A., Picatoste, B., Fardman, B., Ishikawa, K., Mazurek, R., Pieper, M., Sartori, S., Rodriguez-Capitán, J., Fuster, V., & Badimon, J. J. (2023). Cardioprotective Effect of Empagliflozin and Circulating Ketone Bodies During Acute Myocardial Infarction. Circulation: Cardiovascular Imaging, 16(4). https://doi.org/10.1161/circimaging.123.015298

Vancouver

Santos-Gallego CG, Requena-Ibáñez JA, Picatoste B, Fardman B, Ishikawa K, Mazurek R, et al. Cardioprotective Effect of Empagliflozin and Circulating Ketone Bodies During Acute Myocardial Infarction. Circulation: Cardiovascular Imaging. 2023;16(4). doi:10.1161/circimaging.123.015298

BibTeX
@article{SantosGallego2023,
  author = {Santos-Gallego, Carlos G and Requena-Ibáñez, Juan Antonio and Picatoste, Belen and Fardman, Brian and Ishikawa, Kiyotake and Mazurek, Renata and Pieper, Michael and Sartori, Samantha and Rodriguez-Capitán, Jorge and Fuster, Valentin and Badimon, Juan J},
  title = {Cardioprotective Effect of Empagliflozin and Circulating Ketone Bodies During Acute Myocardial Infarction},
  journal = {Circulation: Cardiovascular Imaging},
  year = {2023},
  volume = {16},
  number = {4},
  doi = {10.1161/circimaging.123.015298}
}
Kostenlos starten →